+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Global Induced Pluripotent Stem Cell (iPS Cell) Industry Report 2018-19

  • ID: 4600466
  • Report
  • Region: Global
  • 146 Pages
  • BioInformant
until Dec 31st 2019
1 of 5


  • Axol Bioscience
  • Cynata Therapeutics
  • Fate Therapeutics
  • Lonza
  • Megakaryon Corporation
  • Ncardia
  • MORE

Groundbreaking experimentation in 2006 led to the introduction of induced pluripotent stem cells (iPSCs). These are adult cells which are isolated and then transformed into embryonic-like stem cells through the manipulation of gene expression, as well as other methods. Research and experimentation using mouse cells by Shinya Yamanaka’s lab at Kyoto University in Japan was the first instance in which there was a successful generation of iPSCs.

In 2007, a series of follow-up experiments were done at Kyoto University in which human adult cells were transformed into iPSCs. Nearly simultaneously, a research group led by James Thomson at the University of Wisconsin-Madison accomplished the same feat of deriving iPSC lines from human somatic cells.

Since the discovery of iPSCs a large and thriving research product market has grown into existence, largely because the cells are non-controversial and can be generated directly from adult cells. While it is clear that iPSCs represent a lucrative product market, methods for commercializing this cell type are still being explored, as clinical studies investigating iPSCs continue to increase in number.
iPS Cell Therapies

2013 was a landmark year in Japan because it saw the first cellular therapy involving the transplant of iPS cells into humans initiated at the RIKEN Center in Kobe, Japan. Led by Masayo Takahashi of the RIKEN Center for Developmental Biology (CDB). Dr. Takahashi was investigating the safety of iPSC-derived cell sheets in patients with wet-type age-related macular degeneration.

Although the study was suspended in 2015 due to safety concerns, in June 2016 RIKEN Institute announced that it would resume the clinical study using allogeneic rather than autologous iPSC-derived cells, because of the cost and time efficiencies.

In a world-first, Cynata Therapeutics received approval in September 2016 to launch the world’s first formal clinical trial of an allogeneic iPSC-derived cell product, called “CYP-001.” The study involves centers in the UK and Australia. In this trial, Cynata is testing an iPS cell-derived mesenchymal stem cell (MSC) product for the treatment of GvHD.

On 16 May 2018, Nature News then reported that “Japan’s health ministry gave doctors at Osaka University permission to take sheets of tissue derived from iPS cells and graft them onto diseased human hearts.” The team of Japanese doctors, led by cardiac surgeon Yoshiki Sawa at Osaka University, will use iPS cells to “create a sheet of 100 million heart-muscle cells.” From preclinical studies in pigs, the medical team determined that thin sheets of cell grafts can improve heart function, likely through paracrine signaling.

Kyoto University Hospital in Kobe, Japan also stated it would be opening an iPSC therapy center in 2019, for purposes of conducting clinical studies on iPS cell therapies. Officials for Kyoto Hospital said it will open a 30-bed ward to test the efficacy and safety of the therapies on volunteer patients, with the hospital aiming to initiate construction at the site in February of 2016 and complete construction by September 2019.
iPS Cell Market Competitors

In 2009 ReproCELL, a company established as a venture company originating from the University of Tokyo and Kyoto University was the first to make iPSC products commercially available with the launch of its human iPSC-derived cardiomyocytes, which it called “ReproCario.”

Cellular Dynamics International, a Fujifilm company, is another major market player in the iPSC sector. Similar to ReproCELL, CDI established its control of the iPSC industry after being founded in 2004 by Dr. James Thomson at the University of Wisconsin-Madison, who in 2007 derived iPSC lines from human somatic cells for the first time ever (the feat was accomplished simultaneously by Dr. Shinya Yamanaka’s lab in Japan).

A European leader within the iPSC market is Ncardia, formed through the merger of Axiogenesis and Pluriomics. Founded in 2001 and headquartered in Cologne, Germany, Axiogenesis initially focused on generating mouse embryonic stem cell-derived cells and assays. After Yamanaka’s groundbreaking iPSC technology became available, Axiogenesis was the first European company to license and adopt Yamanaka’s iPSC technology in 2010.

Ncardia’s focus lies on preclinical drug discovery and drug safety through the development of functional assays using human neuronal and cardiac cells, although it is expanding into new areas. Its flagship offering is its Cor.4U human cardiomyocyte product family, including cardiac fibroblasts.

In summary, market leaders have emerged in all areas of iPSC development, including:

  • Drug Development and Discovery: CDI, a Fujifilm Company, in Madison, Wisconsin; Ncardia in Cologne, Germany
  • Cellular Therapy: RIKEN Center, in Kobe, Japan; Kyoto University in Kyoto, Japan; Cynata Therapeutics in Australia
  • Stem Cell Biobanking: CDI, a Fujifilm Company, in Madison, Wisconsin; ORIG3N in Boston, Massachusetts
  • iPSC Research Products: CDI, a Fujifilm Company; Ncardia, ReproCELL; Thermo Fisher Scientific; STEMCELL Technologies; BD Biosciences; Axol Bioscience; and many more

iPS Cell Commercialization

There are four major areas of commercialization for induced pluripotent stem cells, as described below:

  • Drug Development & Discovery: iPSCs have the potential to transform drug discovery by providing physiologically relevant cells for compound identification, target validation, compound screening, and tool discovery.
  • Cellular Therapy: iPSCs are being explored in cellular therapy applications for purposes of reversing injury or disease.
  • Toxicology Screening: iPSCs can be used for toxicology screening, which is the use of stem cells or their derivatives (tissue-specific cells) to assess the safety of compounds or drugs within living cells.
  • Stem Cell Biobanking: iPSC repositories provide researchers with the opportunity to investigate a diverse range of conditions using iPSC-derived cell types produced from both healthy and diseased donors.

iPS Cell Report Key Findings

Key report findings included in this global strategic report include:

  • Market Size Determination for the iPSC Market
  • Market Segmentation by Product Category, Application, and Geography
  • 5 Year Market Projections through 2022
  • Trend Analysis of iPSC Grants
  • Trend Analysis of iPSC Clinical Trials
  • Trend Analysis of iPSC Scientific Publication
  • Analysis of iPSC Patent and IP Environment
  • SWOT Analysis for the iPSC Market
  • Competitive Analysis of iPSC Market Leaders
  • Profiles of iPSC Market Leaders
Note: Product cover images may vary from those shown
2 of 5


  • Axol Bioscience
  • Cynata Therapeutics
  • Fate Therapeutics
  • Lonza
  • Megakaryon Corporation
  • Ncardia
  • MORE

1. Scope And Methodology   

  • Market Definition
  • Market Scope
  • Market Stakeholders
  • Research Methodology
  • Secondary and Primary Research Methodology
  • Market Size Estimation Methodology
  • Market Forecast Methodology
  • Assumptions
  • Years Considered for the Study
  • Currency

2. Executive Summary   

  • Introduction

3. Background - iPSC Research   

  • About iPSCs
  • Importance of iPSCs in Modern Medical Science
  • Evolution of iPSC Research and Application
  • Scientific Discoveries and Progress Since Discovery of iPSCs
  • Potential Future Use of iPSCs
  • Hepatic Differentiation of Human iPSCs
  • Disease Modelling with Human iPSCs
  • Drug Toxicity and Drug Discovery using Human iPSCs
  • Therapeutic Potential of Human iPSCs
  • Present Day Utilizations
  • Drug Development and Discoveries
  • Cellular Therapy
  • Toxicology Screening
  • iPSC Cell Lines and iPSC Banks
  • Cancer Research
  • Recent Research & Clinical Updates
  • Building the World’s Largest iPSC Repository
  • 1st Investigator Led Study with iPSC-derived Product for Macular Degeneration (RIKEN)
  • World’s 1st Trial with Allogeneic iPSC-Derived Therapeutic Product (Cynata Therapeutics)
  • Physician Led Study Using iPSCs for Parkinson’s Disease (Kyoto University)
  • Physician Led Study Using iPSC-derived Cell Sheets for Heart Disease (Osaka University)
  • Moving iPSC-derived Platelets Toward the Clinic (CiRA of Kyoto University)
  • Advantages and Disadvantages of iPSC
  • Advantages of iPSCs
  • Disadvantages of iPSCs
  • Recent Activity: iPSC Research Supply Companies
  • Ncardia and Nanion Technologies
  • FUJFILM Cellular Dynamics and University of California - Irvine
  • Evotec and Celgene
  • Ncardia (Formed by Merger of Pluriomics and Axiogenesis)
  • ID Pharma and Axol Bioscience
  • Evotec and Censo Biotechnologies
  • ORIG3N
  • Fujifilm Establishes CDI Japan
  • Stemgent Company
  • Fujifilm Holdings
  • Recent Activity: iPSC Cell Therapy Companies / Organizations
  • Fate Therapeutics and ONO Pharmaceutical
  • Cynata Therapeutics (Positive Phase I Data)
  • Center for iPS Cell Research & Application (CiRA), Kyoto University
  • Osaka University
  • Fujifilm and Takeda Pharmaceutical
  • BlueRock Therapeutics and Universal Cells
  • Fujifilm Takes Equity Stake in Cynata Therapeutics
  • Cellular Dynamics International (CDI)
  • RIKEN Centre for Developmental Biology (CDB)

3. Market Analysis By Product Category   

  • Market Segments
  • Key Findings
  • Introduction
  • Reprogramming
  • Cell Culture
  • Differentiation
  • Cell Analysis
  • Engineering
  • Others

4. Market Analysis By Application   

  • Key Findings
  • Introduction
  • Academic Research
  • Drug Development & Discovery
  • Cellular Therapy
  • Toxicology Screening
  • Stem Cell Banking

5. Market Analysis By Geography   

  • Key Findings
  • Introduction
  • North America
  • Europe
  • APAC
  • Rest of the World (ROW)

6. Scientific Publications   

  • Key Findings
  • Overview of iPSC Research Activity

7. Patents   

  • Key Findings
  • Introduction
  • Patent List
  • Patents by Geography
  • Commentary
  • Patents by Category
  • Commentary

8. Analysis Of IPSC Market Leaders   

9. Featured Companies: Companies Specializing in iPSC Products   

  • Cellular Dynamics International (CDI), a Fujifilm Company
  • Ncardia
  • Axol Bioscience

10. Featured Companies: Broad Providers of Research Tools to Include iPSC Products   

  • Lonza
  • Thermo Fisher Scientific
  • Takara Bio

11. Featured Companies: Companies Developing iPSC-Derived Cell Therapeutics   

  • Cynata Therapeutics
  • Fate Therapeutics
  • Megakaryon Corporation
  • ORIG3N

12. Conclusions   

List of Figures
Figure 1: Research Methodology Steps
Figure 2: Market Size Estimation Methodology: Bottom-Up Approach
Figure 3: Market Size Estimation Methodology: Top-Down Approach
Figure 4: Research Design
Figure 5: Global Induced Pluripotent Stem Cell Market Estimates - 2017-2022 (USD billion)
Figure 6: Process of iPSC Cell Formation
Figure 7: From Somatic Cell to Treatment
Figure 8: The Leading Applications for Pluripotent Stem Cell Derivatives
Figure 9: iPS Derived Models of Diabetic Cardiomyopathy
Figure 10: Recent Technological Updates and Clinical Applications of Induced Pluripotent Stem Cells
Figure 11: iPSC Technology
Figure 12: Human Induced Pluripotent Stem Cell (hiPSC)-based Platforms for Drug Development
Figure 13: Construction of Carcinogenesis model
Figure 14: iPSCs in Dentistry
Figure 15: Stem Cell Reprogramming
Figure 16: Bad effects of iPSCs
Figure 17: iPSC market Share by Product Type
Figure 18: Share of iPSC Clinical Studies by Region (January 2015 to August 2017)
Figure 19: Percentage Share of Patent Granted by Region (2012-2017)
Figure 20: Percentage Share of Patents by Categories (2012-2017)

List of Tables
Table 1: From Innovation to Commercialization
Table 2: Global iPSC Market, by Product Category, USD Million, 2015 - 2022
Table 3: Global iPSC Reprogramming Market, by Geography, USD Million, 2015 - 2022
Table 4: Global iPSC Cell Culture Market, by Geography, USD Million, 2015 - 2022
Table 5: Global iPSC Differentiation Market, by Geography, USD Million, 2015 - 2022
Table 6: Global iPSC Cell Analysis Market, by Geography, USD Million, 2015 - 2022
Table 7: Global iPSC Engineering Market, by Geography, USD Million, 2015 - 2022
Table 8: Global iPSC Other Product Category Market, by Geography, USD Million, 2015 - 2022
Table 9: Global iPSC Market, by Application, USD Million, 2015 - 2022
Table 10: Global iPSC Market for Academic Research Application, by Geography, USD Million, 2015 - 2022
Table 11: Global iPSC Market for Drug Development & Discovery Application, by Geography, USD Million, 2015 - 2022
Table 12: Global iPSC Market for Cellular Therapy Application, by Geography, USD Million, 2015 - 2022
Table 13: Global iPSC Market for Toxicology Screening Application, by Geography, USD Million, 2015 - 2022
Table 14: Global iPSC Market for Stem Cell Biobanking, by Geography, USD Million, 2015 - 2022
Table 15: iPSC Publication Output, Growth and Citation Impact, by Country (2008 to 2012)
Table 16: Global iPSC Market, by Geography, USD Million, 2015 - 2022
Table 17: North America iPSC Market for Academic Research Application, by Country, USD Million, 2015 - 2022
Table 18: North America iPSC Market, by Product Category, USD Million, 2015 - 2022
Table 19: North America iPSC Market, by Application, USD Million, 2015 - 2022
Table 20: U.S. iPSC Market, by Product Category, USD Million, 2015 - 2022
Table 21: U.S. iPSC Market, by Application, USD Million, 2015 - 2022
Table 22: Europe iPSC Market, by Product Category, USD Million, 2015 - 2022
Table 23: Europe iPSC Market, by Application, USD Million, 2015 - 2022
Table 24: APAC iPSC Market for Academic Research Application, by Country, USD Million, 2015 - 2022
Table 25: APAC iPSC Market, by Product Category, USD Million, 2015 - 2022
Table 26: APAC iPSC Market, by Application, USD Million, 2015 - 2022
Table 27: Japan iPSC Market, by Product Category, USD Million, 2015 - 2022
Table 28: Japan iPSC Market, by Application, USD Million, 2015 - 2022
Table 29: RoW iPSC Market, by Product Category, USD Million, 2015 - 2022
Table 30: RoW iPSC Market, by Application, USD Million, 2015 - 2022

Note: Product cover images may vary from those shown
3 of 5


4 of 5
  • Axol Bioscience
  • Cellular Dynamics International (CDI), a Fujifilm Company
  • Cynata Therapeutics
  • Fate Therapeutics
  • Lonza
  • Megakaryon Corporation
  • Ncardia
  • ORIG3N
  • ReproCELL
  • Takara Bio
  • Thermo Fisher Scientific
Note: Product cover images may vary from those shown
5 of 5

The content and statistics contained within the publisher's reports are compiled using a broad range of sources, as described below.

Input Sources

  • Clinical Trial Databases (ClinicalTrials.gov, International Clinical Trials Registry Platform, European Union Clinical Trials Register, Chinese Clinical Trial Registry, Others)
  • Scientific Publication Databases (PubMed, Highwire Press, Google Scholar)
  • Patent Databases (United States Patent and Trade Office, World Intellectual Property Organization, Google Patent Search)
  • Grant Funding Databases (RePORT Database, CIRM, MRC, Wellcome Trust - UK, Others)
  • Product Launch Announcements (Trade Journals, Google News)
  • Industry Events (Google News, Google Alerts, Press Releases)
  • Company News (SEC Filings, Investor Publications, Historical Performance)
  • Social Analytics (Google Adwords, Google Trends, Twitter, Topsy.com, Hashtagify.me, BuzzSumo.com)
  • Interviews with Stem Cell Industry Leaders

Research & Analysis Methodologies

The publisher employs the following techniques for deriving its market research:

  • Historical Databases: As the first and only market research firm to specialize in the stem cell industry, the publisher has 13+ years of historical data on each segment of the stem cell the industry. This provides an extremely rare and robust database for establishing market size determinations, as well as making future market predictions.
  • Prolific Interviews with Industry Leaders: As the global leader in stem cell industry data, the publisher has interviewed hundreds of leaders from across the stem cell industry, including the CEO of FUJIFILM CDI, FUJIFILM Irvine Scientific, Pluristem Therapies, Celularity, and many others.
  • Industry Relationships: The research team and its President/Founder, Cade Hildreth, Chair and present at a wide range of stem cell industry events, including Phacilitate's Advanced Therapies Week, World Stem Cell Summit (WSCS), Perinatal Stem Cell Society Congress, AABB's International Cord Blood Symposium (ICBS), and other events hosted within the U.S. and worldwide.
  • Global Integrated Feedback: Because the publisher maintains the world's largest stem cell industry news site that is read by nearly a million unique readers per year and the company has large social media audiences (25.7K+ followers on Linked, 21.2K+ followers on Twitter, and 4.3K+ followers on Facebook), the publisher is able to publish content relevant to the industry and receive immediate feedback/input from a global community of readers. In short, the publisher's data is crowd-sourced from market participants worldwide, including those in diverse geographic regions.
  • Preliminary Research: In addition to the interviews described above, the publisher conducts market surveys, executes social media polls, and aggregates market data from stem cell industry announcements, press releases, and corporate filings/presentations.
  • Secondary Research: The publisher summarizes, collects and synthesizes existing market research that is relevant to the market area of interest.
  • Future Projections: Using the resources described above, the publisher is uniquely positioned to make future projections about market size, market growth by segment, market trends, technology evolution, funding activities (financing rounds, M&A, and IPOs), and importantly, market leadership (market share by company).